Global vaccine regulatory pathways: A comparative analysis of approval requirements, clinical evidence, and market convergence
This report presents a comparative regulatory assessment of nine vaccines across respiratory syncytial virus (RSV), pneumococcal, and influenza indications in six major regulatory markets: the European Union (EU), United States (US), Japan, Australia, Canada, and China. The analysis evaluates licensing pathways, approved indications, and clinical evidence packages submitted in support of market authorization to identify areas of regulatory convergence, divergence, and broader approval trends across jurisdictions.
Notably, only one of the nine vaccines assessed achieved approval across all analyzed jurisdictions, underscoring the ongoing challenges of achieving global regulatory alignment. The analysis also revealed several recurring regulatory patterns. Across all three vaccine categories, approvals were typically granted first in the United States, followed by the EU and Canada, with Australia and Japan often authorizing products later in the development lifecycle.
